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Bromfenac, a nonnarcotic analgesic nonsteroidal
anti-inflammatory drug, was associated with re-
versible, minor elevations in serum aminotransfer-
ase levels during clinical trials. The aim of this
study is to describe the clinical, laboratory, and
histological features of 4 patients with severe
bromfenac hepatotoxicity identified at 3 tertiary
care centers participating in the US Acute Liver
Failure Study Group. Bromfenac was adminis-
tered for chronic musculoskeletal disorders to 4
women in therapeutic doses of 25 to 100 mg/d for
a minimum of 90 days. All patients reported a
prodrome of malaise and fatigue and presented
with severe, symptomatic hepatocellular injury
with associated hypoprothrombinemia. None of
the subjects had underlying liver or kidney dis-
ease, and there was no evidence of a hypersensi-
tivity reaction. Other identifiable causes of acute
liver failure were uniformly excluded. Despite
supportive measures, all the subjects developed
progressive liver failure over 5 to 37 days, leading
to emergency liver transplantation in 3 patients
and death in 1 patient while awaiting transplanta-
tion. Extensive confluent parenchymal necrosis
that appeared to begin in the central zones and
was accompanied by a predominantly lympho-
cytic infiltrate was noted in all the livers exam-
ined. Nodular regeneration was seen in the 2
patients with a more protracted clinical course.
Administration of therapeutic doses of bromfenac
for greater than 90 days was associated with the
development of acute liver failure leading to liver
transplantation or death in 4 adult women. The
poor outcomes observed in this series, coupled
with the inability to identify individuals at risk for
severe, idiosyncratic bromfenac hepatotoxicity,
preclude further use of bromfenac in the medical
community.
Copyright r 1999 by the American Association for
the Study of Liver Diseases
B romfenac (Duract; Wyeth-Ayerst Laboratories,Philadelphia, PA), a potent peripherally acting
nonnarcotic analgesic nonsteroidal anti-inflamma-
tory drug (NSAID), was approved for use in the
United States in July 1997.1,2 More than 2.5 million
prescriptions for bromfenac were written until
June 1998, when the drug was voluntarily with-
drawn by the manufacturer because of postmarket-
ing reports of severe hepatotoxicity.3 Only one case
of severe hepatotoxicity caused by bromfenac use
has been reported in the medical literature.4 We
now describe the clinical presentation, laboratory
findings, and liver histological characteristics of 4
patients receiving daily therapeutic doses of bromf-
enac who developed acute liver failure leading to
liver transplantation or death.5
The Acute Liver Failure Study Group (ALFSG)
is a cooperative effort of 14 major US academic
medical centers assembled to gather data regarding
the cause, treatment, and outcome of patients with
acute liver failure.6 In January 1998, the ALFSG
began collecting prospective demographic and clini-
cal data from patients with acute liver failure
presenting to participating centers. From January
1998 through July 1998, a total of 53 cases of acute
liver failure were identified by the ALFSG. Eleven
cases (21%) were attributed to idiosyncratic drug
reactions. Four cases of acute liver failure attrib-
uted to bromfenac ingestion were identified and
form the basis of this report.
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Case Reports
Case 1
A 40-year-old Hispanic woman took bromfenac, 75 mg
daily, for chronic shoulder pain for 3 months. Two weeks
before hospitalization, she was prescribed amoxicillin for
a presumed upper respiratory infection. She took a total
of 4 doses of amoxicillin and 3 doses of acetaminophen
(1500 mg total). She denied a history of occupational
exposure to hepatotoxins, intravenous drug use, recent
alcohol consumption, or foreign travel. Two years before
presentation, she was noted to have normal serum
aminotransferase levels. At the time of hospitalization,
she was afebrile, jaundiced, and lethargic. Bromfenac and
all other medications were immediately discontinued.
Laboratory examination showed the following values:
alanine aminotransferase (ALT), 2983 U/L; aspartate
aminotransferase (AST), 1823 U/L; alkaline phosphatase
(AP), 133 U/L; albumin, 2.8 g/dL; prothrombin time (PT),
65 seconds (international normalized ratio [INR], 8.9);
and total bilirubin, 18 mg/dL. Her white blood cell count
was normal, without eosinophilia. Serum acetamino-
phen level was undetectable. Serological evaluation for
hepatitis (A, B, and C), cytomegalovirus (CMV), herpes
simplex virus, Epstein-Barr virus (EBV), Wilson’s disease,
and autoimmune hepatitis was unremarkable. An abdomi-
nal ultrasound showed no hepatic or biliary abnormalities.
Within 72 hours of transfer to the University of
Michigan Medical Center (Ann Arbor, MI), her mental
status and liver function deteriorated, and she underwent
liver transplantation. The explant showed extensive multi-
lobular confluent necrosis, but in the areas with viable
hepatocytes, the necrosis primarily involved the centri-
lobular areas. Marked microvesicular steatosis of the
nonnecrotic hepatocytes and a diffuse lobular hepatitis
with sinusoidal lymphocytosis was observed (Fig. 1).
The patient is doing well 6 months posttransplantation.
Case 2
A 40-year-old Caucasian woman was prescribed brom-
fenac, 25 mg twice daily, for chronic bilateral shoulder
and musculoskeletal pain. Over the next 8 months, she
experienced excellent pain relief. Her only other medica-
tion was a sedative containing acetaminophen (325 mg)
and diphenhydramine for sleep disturbance. At an outpa-
tient visit 8 weeks before presentation, her serum AST
level was 112 U/L. Two weeks before presentation, she
developed fatigue, jaundice, and weakness and stopped
taking bromfenac. However, she experienced worsening
malaise with nausea, leading to hospitalization. She
denied a history of chronic alcohol use, intravenous drug
use, recent travel, or exposure to known hepatotoxins.
On examination, she was afebrile, well nourished, and
jaundiced. Laboratory evaluation showed the following
values; AST, 2112 U/L, ALT, 4570 U/L; total bilirubin, 7.0
mg/dL; PT, 21 seconds (INR, 2.7), and AP, 120 U/L.
Serological evaluation for hepatitis (A, B, and C), Wil-
son’s disease, CMV, EBV, and autoimmune hepatitis were
negative. An abdominal ultrasound was unremarkable.
Within 3 days of hospitalization at the University of
Michigan Medical Center, her clinical condition deterio-
rated, and she required mechanical ventilation for cere-
bral edema. At liver transplantation 6 days after presenta-
tion, her liver was noted to be small and atrophic. Liver
histological examination showed nearly total necrosis of
the liver parenchyma, with intense periportal and paren-
chymal lymphocytosis. Three months after transplanta-
tion, she is slowly recovering.
Case 3
A 46-year-old Caucasian woman developed fatigue, nau-
sea, and jaundice over 2 weeks. She denied a history of
Figure 1. Histological findings from the liver explant of patient 1. (A) Severe centrilobular necrosis with
parenchymal collapse. (Hematoxylin and eosin, original magnification 320) (B) Prominent microvesicu-
lar steatosis of nonnecrotic hepatocytes with accompanying lobular hepatitis and sinusoidal lymphocy-
tosis. (Hematoxylin and eosin, original magnification 340)
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liver disease, exposure to occupational hepatotoxins,
intravenous drug use, or recent travel. She had a remote
history of regular alcohol ingestion, but had been absti-
nent for 15 years. In the 3 months before presentation,
she had taken 25 to 50 mg of bromfenac daily and one to
two codeine with acetaminophen (325 mg) tablets daily
for chronic shoulder pain. At presentation, she was a
chronically ill-appearing woman with proximal muscle
wasting and jaundice. Laboratory values included the
following: AST, 1101 U/L; ALT, 911 U/L; AP, 186 U/L;
and total bilirubin, 6.9 mg/dL. PT was elevated at 18.5
seconds; INR, 2.4; and serum albumin level was 2.8 g/dL.
Serum acetaminophen level was undetectable. Serologi-
cal evaluation for hepatitis (A, B, C, and E), CMV, EBV,
Wilson’s disease, and autoimmune hepatitis was unre-
markable. An abdominal ultrasound showed a thickened
gallbladder wall.
Four weeks after presentation, the patient was trans-
ferred to the University of Nebraska Medical Center
(Omaha, NE) for further evaluation and treatment.
Laboratory values included AST, 331 U/L; ALT, 305 U/L;
and total bilirubin, 28.3 mg/dL. A transjugular liver
biopsy specimen showed prominent pericentral collapse
with lobular and periportal lymphocytosis. Despite sup-
portive care, the patient developed progressive encepha-
lopathy and coagulopathy over the next 3 weeks, requir-
ing liver transplantation. Evaluation of her explant
showed minimal periportal inflammation, but prominent
lymphocytosis in the areas of collapse. Nodular regenera-
tion with early septate scars accompanied the confluent
necrosis. Six months after transplantation, she continues
to improve.
Case 4
A 60-year-old Caucasian woman was hospitalized with
abdominal pain, jaundice, and syncope.7 She had been
prescribed bromfenac, 25 mg four times daily, for ar-
thritic pain for 3 months before presentation. Her past
medical history included long-standing rheumatoid ar-
thritis, anxiety, and prior thyroidectomy, for which she
was receiving alprazolam, estrogen, progesterone, and
levothyroxine. There was no history of liver disease,
alcohol use, intravenous drug use, recent travel, or
occupational exposure to hepatotoxins. At presentation,
she was jaundiced, without evidence of hepatospleno-
megaly or skin rash. Laboratory values included AST,
601 U/L, and total bilirubin, 2.9 mg/dL. There was no
peripheral eosinophilia, and serum acetaminophen level
was undetectable. Serological evaluation for hepatitis (A,
B, C, and E), CMV, and herpes simplex virus was
negative, and ultrasound examination was unremark-
able. The antinuclear antibody count was mildly positive
at 1:160, and smooth-muscle antibody was undetectable.
Bromfenac was discontinued and despite initial treat-
ment with prednisone, 20 mg/d, the serum AST level
increased to 1810 U/L, and bilirubin level increased to 10
mg/dL.
On hospital day 17, a transjugular liver biopsy at
Oregon Health Sciences University (Portland, OR)
showed bridging necrosis with nodular regeneration and
periportal lymphocytosis, but minimal lobular inflamma-
tion. Prednisone therapy was discontinued, but unfortu-
nately the patient developed progressive ascites and
encephalopathy and died of multiorgan failure on hospi-
tal day 37. At postmortem, the liver weighed 700 g and
histological evaluation showed submassive hepatic necro-
sis with residual islets of hepatocytes and a lymphocytic
infiltrate in areas of collapse, but not in the regenerative
nodules.
Discussion
The daily dose of bromfenac administered to these
patients with severe hepatotoxicity was within the
recommended prescribing guideline of less than
150 mg/d.2 However, each subject took bromfenac
for periods of time exceeding the 10-day maximum
recommended by the manufacturer, and serial
monitoring of aminotransferase levels was not
routinely performed (Table 1). None of the subjects
had known liver or kidney disease, and none were
receiving other medications, such as cimetidine or
phenytoin, that are known to alter the bioavailabil-
Table 1. Clinical Features and Outcome With Severe Bromfenac Hepatotoxicity
Patient


















1 40/F H 3 75 2983 8.9 18 5 Transplant
2 42/F C 10 50 4570 4.1 47 6 Transplant
3 46/F C 3 50 911 4.0 50 33 Transplant
4 60/F C 3 100 1380 4.1 25 37 Death
Abbreviations: H, Hispanic; C, Caucasian; Max, maximum; Bili, bilirubin.
*Days from hospitalization to identified outcome.
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ity of bromfenac.2,8 A thorough evaluation in each
case failed to show another identifiable cause of
acute liver failure. Although subjects 1, 2, and 3
received therapeutic doses of acetaminophen for
short periods of time, the progressive nature,
clinical course, and histological findings observed
are not consistent with surreptitious acetamino-
phen hepatotoxicity.9 All the subjects denied a
history of intolerance to other NSAIDs, and none
had evidence of a hypersensitivity reaction. Al-
though none of the subjects were rechallenged with
bromfenac, the temporal relationship between
bromfenac use and the development of liver injury
are suggestive of an idiosyncratic reaction to brom-
fenac as the presumed cause of liver failure.10,11
The observation that all of the afflicted patients
were adult women may relate to the demographics
of NSAID use.12,13 The severe hepatocellular injury
pattern at presentation and the progressive coagu-
lopathy and encephalopathy observed in all pa-
tients is consistent with a clinical syndrome of
acute liver failure.14 Despite prompt discontinua-
tion of bromfenac and supportive care, none of the
subjects spontaneously recovered.
Liver histological examination correlated with
the duration of clinical illness (Table 2). The 2
subjects with the most rapid clinical deterioration
(subjects 1 and 2) had the most severe necrosis and
collapse, whereas the 2 subjects with a more
protracted clinical course (subjects 3 and 4) showed
evidence of nodular hepatic regeneration. All the
livers showed extensive confluent parenchymal
necrosis that possibly began in the central zone,
suggestive of a toxic cause. In addition, an intense
lobular and periportal hepatitis composed predomi-
nantly of lymphocytes was noted. A similar hetero-
geneity of histological findings in patients present-
ing with acute liver failure caused by drugs and
other causes has been noted.15
Severe NSAID hepatotoxicity leading to hospital-
ization or death is rare. However, because of their
enormous worldwide consumption, NSAIDs have
become an important class of drugs responsible for
drug-induced liver injury.12 During clinical trials,
bromfenac, like other NSAIDs, was associated with
a mild elevation in serum aminotransferase levels
(,3 times the upper limit of normal [ULN]) in up
to 15% of treated patients.2 Moderate to severe
serum aminotransferase elevations (.3 times ULN)
were noted in 2.7% of treated patients and marked
elevations (.8 times ULN) in 0.4% of treated patients.
The serum aminotransferase elevations appeared to
be reversible on cessation of bromfenac use. The
incidence of severe bromfenac hepatotoxicity is
unknown because sporadic cases may be underre-
ported, and aminotransferase monitoring is not
commonly performed in patients receiving NSAIDs.
The association of prolonged use of bromfenac
with the development of severe hepatotoxicity in
our series and other reports suggests that a toxic
metabolite may be involved in the etiopathogen-
esis.4,16 Bromfenac, a benzene acetic acid deriva-
tive, is rapidly and extensively metabolized in the
liver after absorption from the intestinal lumen.
Although the hepatic enzyme(s) responsible for
bromfenac metabolism in vivo are not well charac-
terized, glucoronide conjugates of aglycone metabo-
lites of bromfenac can be detected in the urine after
oral ingestion.17 The striking microvesicular steato-
sis in the liver tissue of one of the study subjects
(subject 1) is similar to that described in other
cases of idiosyncratic NSAID hepatotoxicity.18,19
However, whether the steatosis reflects drug-
induced mitochondrial toxicity or is simply a
marker of NSAID use is unclear.20,21
Other NSAIDs have been withdrawn from the
marketplace because of an unacceptably high rate
of severe or fatal hepatotoxicity reported during
postmarketing surveillance.22 The failure to detect
such severe hepatotoxicity during drug develop-
ment in part relates to the relatively short time
during which patients are studied, the small num-














1 1111 111 1 111 – 500
2 1111 111 11 1 – 440
3 1111 1 – 1 11 820
4 1111 1 1 2 11 700
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bers of patients involved in clinical trials, and the
infrequent occurrence of such severe reactions.23
The patients reported in this case series had severe
hepatotoxicity at presentation that did not improve
despite drug cessation and supportive measures.
Female sex and daily bromfenac use in excess of 90
days were the only identifiable risk factors. The
poor outcomes observed in this series, coupled
with the inability to identify individuals at risk,
precludes the continued use of bromfenac in the
general medical community.
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